Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States
Top Cited Papers
- 9 January 2016
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (2), 169-+
- https://doi.org/10.1200/JCO.2015.61.5906
Abstract
Purpose To estimate the overall survival (OS) impact from increasing time to treatment initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC). Methods Using the National Cancer Data Base (NCDB), we examined patients who received curative therapy for the following sites: oral tongue, oropharynx, larynx, and hypopharynx. TTI was the number of days from diagnosis to initiation of curative treatment. The effect of TTI on OS was determined by using Cox regression models (MVA). Recursive partitioning analysis (RPA) identified TTI thresholds via conditional inference trees to estimate the greatest differences in OS on the basis of randomly selected training and validation sets, and repeated this 1,000 times to ensure robustness of TTI thresholds. Results A total of 51,655 patients were included. On MVA, TTI of 61 to 90 days versus less than 30 days (hazard ratio [HR], 1.13; 95% CI, 1.08 to 1.19) independently increased mortality risk. TTI of 67 days appeared as the optimal threshold on the training RPA, statistical significance was confirmed in the validation set (P < .001), and the 67-day TTI was the optimal threshold in 54% of repeated simulations. Overall, 96% of simulations validated two optimal TTI thresholds, with ranges of 46 to 52 days and 62 to 67 days. The median OS for TTI of 46 to 52 days or fewer versus 53 to 67 days versus greater than 67 days was 71.9 months (95% CI, 70.3 to 73.5 months) versus 61 months (95% CI, 57 to 66.1 months) versus 46.6 months (95% CI, 42.8 to 50.7 months), respectively (P < .001). In the most recent year with available data (2011), 25% of patients had TTI of greater than 46 days. Conclusion TTI independently affects survival. One in four patients experienced treatment delay. TTI of greater than 46 to 52 days introduced an increased risk of death that was most consistently detrimental beyond 60 days. Prolonged TTI is currently affecting survival. (C) 2015 by American Society of Clinical OncologyThis publication has 50 references indexed in Scilit:
- Deintensification Candidate Subgroups in Human Papillomavirus–Related Oropharyngeal Cancer According to Minimal Risk of Distant MetastasisJournal of Clinical Oncology, 2013
- Growth in the Use of PET for Six Cancer Types After Coverage by Medicare: Additive or Replacement?Journal of the American College of Radiology, 2012
- Wait Times for Cancer Surgery in the United StatesAnnals of Surgery, 2011
- Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trialThe Lancet Oncology, 2011
- Reduction in waiting time for diagnosis and treatment of head and neck cancer – a fast track studyActa Oncologica, 2011
- The Future of Radiation Oncology in the United States From 2010 to 2020: Will Supply Keep Pace With Demand?Journal of Clinical Oncology, 2010
- Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period AnalysisThe Oncologist, 2010
- Human Papillomavirus and Survival of Patients with Oropharyngeal CancerThe New England Journal of Medicine, 2010
- The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United StatesAnnals of Surgical Oncology, 2008
- Patient factors associated with delay in primary care among patients with head and neck carcinoma: a case-series analysisFamily Practice, 2005